A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and

Recruiting

99 years or below

All

Phase 3

1 Location

Brief description of study

The study will enroll subjects who have completed Study M16-067 or Study M16-065 and have achieved clinical response, defined as decrease from Baseline of induction study of Adapted Mayo score greater than or equal to 2 points and greater than or equal to 30%, PLUS a decrease in rectal bleeding sub-score (RBS) greater than or equal to 1 or an absolute RBS less than or equal to 1 .

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: ulcerative colitis
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 829889

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

Brief description of study

Eligibility of study

Find a site